Achilles Therapeutics

OverviewSuggest Edit

Achilles Therapeutics is a developer of immunotherapies intended to offer therapies to treat cancer. Its immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
TypePrivate
Founded2016
HQLondon, GB
Websiteachillestx.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2020)153
Job Openings20
Share Price (Sept 2021)$6.5
Cybersecurity ratingAMore

Key People/Management at Achilles Therapeutics

Iraj Ali

Iraj Ali

Chief Executive Officer
Karl Peggs

Karl Peggs

Chief Medical Officer
Sergio Quezada

Sergio Quezada

Chief Scientific Officer
Robert Coutts

Robert Coutts

Chief Financial Officer
Beverley Carr

Beverley Carr

Chief Business Officer
Daniel Hood

Daniel Hood

Chief Legal Officer
Show more

Achilles Therapeutics Office Locations

Achilles Therapeutics has offices in London and Stevenage
London, GB (HQ)
Bechtel House, 245 Hammersmith Rd, Hammersmith
Stevenage, GB
Gunnels Wood Rd
Show all (2)

Achilles Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2016

Achilles Therapeutics total Funding

$138.1 m

Achilles Therapeutics latest funding size

$120.98 m

Time since last funding

2 years ago

Achilles Therapeutics investors

Achilles Therapeutics's latest funding round in September 2019 was reported to be $121 m. In total, Achilles Therapeutics has raised $138.1 m
Show all financial metrics

Achilles Therapeutics Revenue

USD

Net income (FY, 2020)

(33.2m)

EBIT (FY, 2020)

(33.7m)

Cash (31-Dec-2020)

177.8m
USDFY, 2019FY, 2020

General and administrative expense

4.7m11.1m

R&D expense

9.1m22.6m

Operating expense total

13.8m33.7m

EBIT

(13.8m)(33.7m)
USDFY, 2019FY, 2020

Cash

97.6m177.8m

Accounts Receivable

5.5m9.9m

Current Assets

103.1m187.8m

PP&E

1.6m13.4m
USDFY, 2019FY, 2020

Net Income

(14.0m)(33.2m)

Depreciation and Amortization

302.0k772.0k

Cash From Operating Activities

(14.1m)(25.3m)

Purchases of PP&E

(942.0k)(11.8m)
USDFY, 2019

Financial Leverage

1 x
Show all financial metrics

Achilles Therapeutics Operating Metrics

FY, 2020May, 2021

Manufacturing Space, sq. ft.

64.18 k

Office and Laboratory Space, square feet

24.63 k

Trademarks (US)

3
Show all operating metrics

Achilles Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

SecurityScorecard logo

Achilles Therapeutics Online and Social Media Presence

Embed Graph

Achilles Therapeutics News and Updates

Achilles Therapeutics to Present at Upcoming Investor Conferences

LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will present at the following investor conferences in September.

Achilles Therapeutics Announces Grant of US and European Patents

LONDON, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that US patent US 11,098,121 and European patent EP3347039B have been granted. The patents cov…

Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

– Presentations of translational science data at AACR and ASCO illustrate crucial path to potency assay –

Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

- Patient enrolled at the Moffitt Cancer Center, FL where Dr. Benjamin Creelan is the Principal Investigator -

Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

LONDON, United Kingdom, June 04, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 20…

Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

- Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned -
Show more

Achilles Therapeutics Blogs

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

Stevenage, UK 7 July 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that... The post Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer appeared first on Achilles Therapeutics.

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that... The post Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer appeared f…

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

Stevenage, UK 29 May 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that... The post Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with…

Achilles Therapeutics to present at Jefferies Virtual Healthcare Conference

Stevenage, UK 28 May, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel... The post Achilles Therapeutics to present at Jefferies Virtual Healthcare Conference appeared first on Achilles Therapeut…

Achilles Therapeutics announces formation of Scientific Advisory Board

– World-leading experts in oncology, immunology and R&D will advise the Company as it advances pipeline of pioneering cancer therapies –... The post Achilles Therapeutics announces formation of Scientific Advisory Board appeared first on Achilles Therapeutics.

Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

Stevenage, UK 22 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel... The post Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting appeared firs…
Show more

Achilles Therapeutics Frequently Asked Questions

  • When was Achilles Therapeutics founded?

    Achilles Therapeutics was founded in 2016.

  • Who are Achilles Therapeutics key executives?

    Achilles Therapeutics's key executives are Iraj Ali, Karl Peggs and Sergio Quezada.

  • How many employees does Achilles Therapeutics have?

    Achilles Therapeutics has 153 employees.

  • Who are Achilles Therapeutics competitors?

    Competitors of Achilles Therapeutics include Instil Bio, Iovance Biotherapeutics and Kite Pharma.

  • Where is Achilles Therapeutics headquarters?

    Achilles Therapeutics headquarters is located at Bechtel House, 245 Hammersmith Rd, Hammersmith, London.

  • Where are Achilles Therapeutics offices?

    Achilles Therapeutics has offices in London and Stevenage.

  • How many offices does Achilles Therapeutics have?

    Achilles Therapeutics has 2 offices.